Les freins à l'utilisation des bêtabloquants chez les patients hypertendus à risque métabolique : aspects cliniquesZANNAD, Faïez.Archives des maladies du coeur et des vaisseaux. Pratique. 2007, Num 157, pp 9-11, issn 1261-694X, 3 p., SUPConference Paper

Acute heart failure syndromes: the 'Cinderella' of heart failure researchZANNAD, Faiez.European heart journal supplements. 2005, Vol 7, Num B, pp B8-B12, issn 1520-765XConference Paper

Reducing Cardiovascular Risk: Evidence From the ONTARGET ProgrammeFERRARI, Roberto; ZANNAD, Faiez.European heart journal supplements. 2009, Vol 11, Num F, issn 1520-765X, 55 p.Conference Proceedings

Benefits of first-line combination of perindopril and indapamide in clinical practice for patients with hypertension and diabetesZANNAD, Faiez.American journal of hypertension. 2007, Vol 20, Num 7, issn 0895-7061, 9S-14S, SUPConference Paper

The potential advantages of a modern antihypertensive therapy in the elderlyZANNAD, Faiez.Journal of cardiovascular pharmacology. Supplement. 2000, Vol 35, Num 1, pp S19-S23Conference Paper

Loop diuretics and ultrafiltration in heart failureROSSIGNOL, Patrick; ZANNAD, Faiez.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 12, pp 1641-1648, issn 1465-6566, 8 p.Article

Les recommandations et le guide « Affections de longue durée » dans l'hypertension artérielle sévère : Hypertensions artérielles particulières = Official recommendations and guidelines for the management and reimbursement of severe hypertension as a chronic diseaseBOIVIN, Jean-Marc; ZANNAD, Faiez.La Presse médicale (1983). 2009, Vol 38, Num 4, pp 652-660, issn 0755-4982, 9 p.Article

Acute heart failure syndromes: a reassessment of current therapiesGHEORGHIADE, Mihai; ZANNAD, Faiez.European heart journal supplements. 2005, Vol 7, Num B, issn 1520-765X, 32 p.Conference Proceedings

Targeting blood pressure in the management of total cardiovascular riskMANCIA, Giuseppe; CORRAO, Giovanni.European heart journal supplements. 2009, Vol 11, Num F, issn 1520-765X, F27-F32Conference Paper

The rationale for choosing telmisartan and ramipril in the ONTARGET programmeUNGER, Thomas.European heart journal supplements. 2009, Vol 11, Num F, issn 1520-765X, F3-F8Conference Paper

Sympathetic-leptin relationship in obesity : effect of weight lossQUILLOT, Didier; BÖHME, Philip; ZANNAD, Faiez et al.Metabolism, clinical and experimental. 2008, Vol 57, Num 4, pp 555-562, issn 0026-0495, 8 p.Article

Reassessing treatment of acute heart failure syndromes: the ADHERE RegistryGHEORGHIADE, Mihai; FILIPPATOS, Gerasimos.European heart journal supplements. 2005, Vol 7, Num B, pp B13-B19, issn 1520-765XConference Paper

Benefits, challenges, and registerability of the polypillSLEIGHT, Peter; POULEUR, Hubert; ZANNAD, Faiez et al.European heart journal. 2006, Vol 27, Num 14, pp 1651-1656, issn 0195-668X, 6 p.Article

Information du public sur les essais cliniques et la recherche = Public information about clinical trials and researchPLETAN, Yannick; ZANNAD, Faïez; JAILLON, Patrice et al.Thérapie (Paris). 2003, Vol 58, Num 3, pp 185-208, issn 0040-5957, 24 p.Conference Paper

Prevention of stroke: new evidenceDAHLÖF, Björn.European heart journal supplements. 2009, Vol 11, Num F, issn 1520-765X, F33-F38Conference Paper

Vascular protection: telmisartan in the ONTARGET Trial ProgrammeDAGENAIS, Gilles R.European heart journal supplements. 2009, Vol 11, Num F, issn 1520-765X, F47-F53Conference Paper

Impaired response of cardiac autonomic nervous system to glucose load in severe obesityQUILLIOT, Didier; ZANNAD, Faiez; ZIEGLER, Olivier et al.Metabolism, clinical and experimental. 2005, Vol 54, Num 7, pp 966-974, issn 0026-0495, 9 p.Article

Pharmacological options for acute heart failure syndromes: current treatments and unmet needsNIEMINEN, Markku S.European heart journal supplements. 2005, Vol 7, Num B, pp B20-B24, issn 1520-765XConference Paper

Nesiritide: new hope for acute heart failure syndromes?BURNETT, John C.European heart journal supplements. 2005, Vol 7, Num B, pp B25-B30, issn 1520-765XConference Paper

Lecture critique, évaluation, valorisation, information sur les résultats des grands essais cliniques = The results of major clinical trials : Critical assessment, the circulation of information aand media coverageFOUCHARD, Marie; ZANNAD, Faiez.Thérapie (Paris). 2004, Vol 59, Num 3, pp 317-322, issn 0040-5957, 6 p.Conference Paper

Of fads, fashion, surrogate endpoints and dual RAS blockadeMESSERLI, Franz H; STAESSEN, Jan A; ZANNAD, Faiez et al.European heart journal. 2010, Vol 31, Num 18, pp 2205-2208, issn 0195-668X, 4 p.Article

The results of major clinical trials: Critical assessment, the circulation of information and media coverageFOUCHARD, Marie; ZANNAD, Faiez.Thérapie (Paris). 2004, Vol 59, Num 3, pp 323-328, issn 0040-5957, 6 p.Conference Paper

Treatment of congestive heart failure: Interfering the aldosterone-cardiac extracellular matrix relationshipZANNAD, Faiez; DOUSSET, Brigitte; ALLA, Francois et al.Hypertension (Dallas, Tex. 1979). 2001, Vol 38, Num 5, pp 1227-1232, issn 0194-911XConference Paper

L'amlodipine face aux mécanismes de l'hypertrophie vasculaire = Amlodipine and the mechanisms of vascular hypertrophyMARCHE, Pierre.Drugs (Basel). 2000, Vol 59, pp 1-7, issn 0012-6667, NS2Article

Role of biomarkers in guiding treatment with aldosterone-blocking agentsZANNAD, Faiez; KETELSLEGERS, Jean-Marie; BRAMLAGE, Peter et al.European heart journal supplements. 2011, Vol 13, Num B, issn 1520-765X, B31-B35Article